On the occasion of the 20th anniversary of the REIN (French Renal Epidemiology and Information Network), a summary work on the contributions of the national French ESKD register was carried out. On the issue of its international role, the following key messages were retained. Right from its inception, the REIN registry has been integrated into the family of European registries under the direction of the European society ERA and its registry based at the Academic Medical Centre of Amsterdam. In this context, the registry has been a part of numerous international publications and projects financed by the European Commission. The expertise of the Agency of Biomedicine and REIN on the registries has been sought on several occasions in the context of setting up registries of replacement therapies. Several foreign students outside the European Union have also been able to come and work in the REIN national coordination.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S1769-7255(22)00576-4 | DOI Listing |
Global Health
January 2025
Department of Global Health Hans Rosling Center, University of Washington, 3980 15th Ave NE, Seattle, Seattle, WA, 98105, USA.
Background: The Covid pandemic and its aftermath have triggered new alarm and social unrest across the Global South over the deepening international debt crisis that now threatens to derail Universal Health Coverage (UHC), other Sustainable Development Goals (SDGs), future pandemic preparedness, and global warming mitigation. The recent Globalization and Health article by Alex Kentikelenis and Thomas Stubbs (May 2024), "Social protection and the International Monetary Fund: promise versus performance", offers a meticulously quantified rendering of the social costs imposed by the crisis and takes aim at IMF solutions. They advocate for a rejection of IMF austerity programs and offer a valuable prescription for change through the International Labor Organization's "Universal Social Protection" concept.
View Article and Find Full Text PDFMicromachines (Basel)
November 2024
Laboratory of Process Engineering, NeptunLab, Department of Microsystems Engineering (IMTEK), University of Freiburg, 79110 Freiburg im Breisgau, Germany.
Fused deposition modeling (FDM) is well suited for microfluidic prototyping due to its low investment cost and a wide range of accessible materials. Nevertheless, most commercial FDM materials exhibit low chemical and thermal stability. This reduces the scope of applications and limits their use in research and development, especially for on-chip chemical synthesis.
View Article and Find Full Text PDFFr J Urol
October 2024
Service d'urologie et transplantation rénale, centre hospitalier universitaire Lapeyronie, Montpellier, France.
Introduction: This case study describes the clinical, medical and administrative management of kidney cancer secondary to occupational exposure to trichloroethylene, a chlorinated solvent classified as a known carcinogen by the International Agency for Research on Cancer.
Method: Data were collected from the computerized records of all patients treated by the occupational medicine department of Montpellier University Hospital for kidney cancer following occupational exposure to trichloroethylene.
Results: The study included five patients aged between 36 and 64years.
Angew Chem Int Ed Engl
January 2025
Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128, Mainz, Germany.
Polyoxometalates (POMs) are ideal components for reversible multi-electron storage in energy technologies. To-date, most redox-applications employ only single, individual POM species, which limits the number of electrons that can be stored within a given potential window. Here, we report that spontaneous redox self-equilibration during cluster synthesis leads to the formation of two structurally related polyoxovanadates which subsequently aggregate into co-crystals.
View Article and Find Full Text PDFClin Drug Investig
November 2024
Paris and Department of Nephrology, Association Pour l'Utilisation du Rein Artificiel (AURA), Ambroise Paré University Medical Center, APHP, Paris, France.
Background And Objective: The efficacy and safety of empagliflozin in the treatment of chronic kidney disease (CKD) were demonstrated in the EMPA-KIDNEY trial, which showed a 28% reduction in combined risks of kidney disease or death from cardiovascular causes (hazard ratio, 0.72; 95% confidence interval, 0.64-0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!